Avian Mycobacteriosis Study Guide

Overview and Clinical Importance

Avian mycobacteriosis (often incorrectly termed "avian tuberculosis") is a chronic, progressive, granulomatous disease affecting companion, captive exotic, wild, and domestic birds worldwide. This disease is caused by non-tuberculous mycobacteria (NTM), most commonly Mycobacterium avium subsp. avium (MAA) and Mycobacterium genavense. The condition is characterized by insidious onset, prolonged disease course, poor prognosis, and significant zoonotic potential, particularly for immunocompromised individuals.

Mycobacteriosis represents a World Organization for Animal Health (WOAH) List B disease due to its socio-economic and public health significance. Understanding this disease is essential for NAVLE success, as questions frequently focus on species predisposition, clinical presentation, diagnostic approaches, zoonotic considerations, and the challenging decision between treatment and euthanasia.

Etiology and Causative Agents

Mycobacteria are acid-fast, Gram-positive, slow-growing, aerobic bacilli characterized by a waxy, lipid-rich cell wall containing mycolic acids. This unique cell wall structure confers resistance to conventional staining (requiring Ziehl-Neelsen or Fite-Faraco stains), environmental persistence, and resistance to many antimicrobials.

Primary Etiologic Agents

Epidemiology and Transmission

Species Susceptibility

All avian species are susceptible, but susceptibility varies significantly. Chickens, pheasants, and partridges are highly susceptible; turkeys are moderately susceptible; waterfowl (ducks and geese) appear relatively resistant. Among pet birds, Brotogeris parakeets, Amazon parrots, and canaries show increased susceptibility. The disease predominantly affects older birds due to the long incubation period required for clinical disease manifestation.

Transmission Routes

Oral-fecal transmission is the primary route, occurring through ingestion of contaminated feed, water, or environmental materials (soil) contaminated with excreta from infected birds. Mycobacteria persist in the environment for years, maintaining infectivity in soil and on surfaces. Aerosol transmission (inhalation) is a secondary route, particularly important in pigeons, waterfowl, and some finches where primary respiratory lesions predominate.

• Primary route: Ingestion of contaminated feed/water/soil
• Secondary route: Inhalation of aerosolized organisms
• Environmental persistence: Mycobacteria survive years in soil
• Incubation period: Months to years (chronic, insidious disease)

Pathophysiology

Following ingestion, mycobacteria invade the intestinal mucosa and are phagocytosed by macrophages. The hallmark of mycobacterial pathogenesis is their ability to survive and replicate within macrophages by preventing phagosome-lysosome fusion. This intracellular survival triggers a cell-mediated immune response, resulting in granuloma formation.

The disease progresses through three phases: latent phase (bacteria establish infection without clinical signs), lesion development phase (granulomas form in target organs), and cachexia phase (wasting, organ failure, death). The chronic immunologic battle leads to progressive tissue destruction while organisms continue to replicate within macrophages.

Target Organ Involvement

Clinical Signs and Presentation

Clinical signs are non-specific and insidious, developing over months to years. Many birds are asymptomatic until advanced disease. Birds may appear normal until shortly before death. The classic presentation is a chronically wasting bird with progressive deterioration despite a normal or increased appetite.

Common Clinical Signs

• Progressive weight loss/cachexia: Despite normal appetite; prominent keel ("knife-edge" sternum)
• Pectoral muscle atrophy: Bird feels lighter than expected when handled
• Depression and lethargy: Decreased activity; fluffed feathers
• Diarrhea: Chronic, often with biliverdinuria (green urates)
• Hepatomegaly: Palpable enlarged liver; abdominal distension
• Poor feather quality: Broken, dull, or stress bars on feathers
• Lameness: From bone involvement; may have pathologic fractures
• Dyspnea: If respiratory involvement (more common in pigeons)
• Decreased egg production: In laying hens

W - Weight loss (chronic, progressive) A - Appetite often preserved S - Splenomegaly and hepatomegaly T - Tubercles (granulomas) in organs I - Intestinal involvement (diarrhea) N - Non-specific signs initially G - Greenish droppings (biliverdinuria)

Diagnosis

Antemortem diagnosis is challenging due to non-specific clinical signs and the chronic nature of disease. Definitive diagnosis often requires multiple diagnostic modalities and may only be confirmed at necropsy.

Diagnostic Approach

Histopathology Findings

Microscopic examination reveals granulomatous inflammation characterized by: epithelioid macrophages (often in sheets), multinucleated giant cells (Langhans-type), central caseous necrosis surrounded by lymphocytes and fibrosis. Unlike mammalian tuberculosis, avian mycobacteriosis typically shows NUMEROUS acid-fast bacilli within macrophages on Ziehl-Neelsen or Fite-Faraco staining.

Differential Diagnosis

Diseases causing hepatomegaly with nodular lesions must be differentiated from mycobacteriosis:

• Lymphoid leukosis/Marek's disease: Tumor infiltrates; no acid-fast organisms
• Coligranuloma (Hjarre's disease): E. coli associated; no acid-fast organisms
• Pseudotuberculosis (Yersinia): Common in ducks/turkeys; bacterial culture differentiates
• Fowl cholera (Pasteurella): Acute presentation; septicemia
• Histomoniasis (blackhead): Cecal cores; liver targets; protozoan
• Aspergillosis: Respiratory focus; fungal hyphae on histopath

Treatment

Treatment is controversial and often NOT recommended due to: prolonged duration (6-12 months or longer), high cost, poor efficacy, high drug resistance rates, zoonotic risk during treatment, and inability to verify cure. However, for high-value birds where euthanasia is not acceptable to owners, treatment may be attempted.

Antimicrobial Protocol

Treatment requires combination therapy with 3+ drugs administered concurrently for a minimum of 6-12 months or longer to prevent resistance development.

Prognosis

• Guarded to poor for all cases
• Birds with advanced disease and granuloma formation have POOR prognosis
• Treatment success is rare and difficult to verify
• Drug resistance is common, especially to ethambutol
• Relapse is common after discontinuing treatment

Zoonotic Considerations

Avian mycobacteriosis has ZOONOTIC POTENTIAL, though risk to immunocompetent adults is considered low. The primary concern is for immunocompromised individuals.

At-Risk Human Populations

• HIV/AIDS patients (especially CD4 count less than 50)
• Chemotherapy patients
• Organ transplant recipients on immunosuppression
• Very young children
• Elderly individuals
• Patients on immunosuppressive medications (steroids, biologics)

Client Communication

CRITICAL: Owners MUST be informed of zoonotic potential. Recommend consultation with their physician, especially if household members are immunocompromised. Infected birds should ideally be euthanized; if treatment is attempted, strict hygiene protocols must be implemented.

Prevention and Control

In Commercial Poultry

• All-in/all-out management: Rapid turnover prevents disease development
• Depopulation: Remove all affected birds and contacts
• Environmental decontamination: Remove topsoil; use tuberculocidal disinfectants
• Avoid mixing ages: Older birds are reservoirs
• Exclude wild birds: Potential transmission from pigeons, wild birds

In Pet Bird Collections/Aviaries

• Quarantine: New birds for minimum 60-90 days
• Screening: CBC, fecal PCR before introducing new birds
• Euthanize infected birds: Most effective control measure
• Contact exposure: All birds in shared environment for past years are "exposed"
• Disinfection: Use tuberculocidal agents (quaternary compounds like Virostat TBQ)
• No vaccine available: Prevention relies on biosecurity